ProCE Banner Activity

CE

Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies

Video

On-demand webcast of expert faculty presentation and case discussion on current evidence and strategies for using bispecific antibodies in hematologic malignancies, as presented at CCO and PCE’s APPlexus Hot Topics 2024.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Released: June 05, 2024

Expiration: December 30, 2024

Share

Faculty

Sherry Adkins

Sherry Adkins, MSN, ANP-C, FAAN

Advanced Practice Provider Supervisor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC in partnership with Partners for Advancing Clinical Education (PACE) and Practicing Clinicians Exchange, LLC

ProCE Banner

Supporters

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Partners

Partners for Advancing Clinical Education (PACE)

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Target Audience

This program is intended for physician associates, oncology nurses and other healthcare professionals who care for patients with hematologic malignancies.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners to safely and effectively integrate bispecific antibody therapy into practice to optimize patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with hematologic malignancies

  • Employ strategies to care for patients with hematologic malignancies treated with bispecific antibody–based therapeutic strategies, taking into consideration current indications, safety profiles, administration considerations, and expert guidance

  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with hematologic malignancies

  • Provide equitable and inclusive patient communication and counseling for patients receiving bispecific antibody therapy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Sherry Adkins, MSN, ANP-C, FAAN

Advanced Practice Provider Supervisor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Sherry Adkins, MSN, ANP-C, FAAN, has no relevant financial relationships to disclose.

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO: consultant/advisor/speaker: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Sanofi.

The planners and content peer reviewers from Clinical Care Options, LLC, Partners for Advancing Clinical Education (PACE), and Practicing Clinicians Exchange, LLC, do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 05, 2024, through December 30, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

Joint Accreditation

 

 

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour,.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until December 30, 2024. PAs should only claim credit commensurate with the extent of their participation.